Extracorporeal Magnetic Innervation—an FDA-cleared therapy supported by more than 25 years of peer-reviewed research—is the technology behind the Gazelle Chair.
CLEARWATER, FL, UNITED STATES, July 15, 2026 /EINPresswire.com/ — Clinical examinations reveal that by their late 60s, nearly all women—up to 97.7 percent—exhibit some level of pelvic organ prolapse, while roughly 62 percent of adult women in the United States, around 78 million, experience urinary incontinence. Despite these numbers, the common advice offered to women is limited to pads, medication, or surgery. Bedrock Bioscience aims to shift that paradigm. The company has announced the wider rollout of the Gazelle Chair, a non-invasive solution for urinary incontinence and pelvic floor dysfunction that is now accessible through an expanding group of providers across the country. The Gazelle Chair relies on Extracorporeal Magnetic Innervation (ExMI), an FDA-cleared modality with more than 25 years of published research behind it, and has been used in the treatment of more than 15,000 patients over the lifespan of the technology.
“For years, I believed that leaking while laughing or running was just an unsolvable part of motherhood — I reached the point where I needed four pads just to get through a 30-minute jog. I was too embarrassed to talk about it, and the surgical options I was given felt like a risk I wasn’t willing to take. After just seven sessions in the Gazelle Chair, the change has been life-changing. I’ve been pad-free for months and have regained the freedom to run and live my life without fear.”
— Kim, Gazelle Chair patient
Individual results may vary.
A 2022 peer-reviewed analysis of CDC survey data published in Urogynecology (formerly Female Pelvic Medicine & Reconstructive Surgery; Patel et al., 2022) found that urinary incontinence affects nearly 62 percent of adult women in the United States—approximately 78 million women. The root issue becomes almost universal with age: upon clinical examination, up to 97.7 percent of women demonstrate some form of pelvic organ prolapse, a weakening of the same pelvic floor muscles, with both occurrence and seriousness growing over time (Lousquy et al., 2009). Although these conditions are extremely prevalent, many women silently endure them for years, frequently under the impression that their only paths forward are invasive surgery, long-term medication, or simply tolerating the condition indefinitely. The Gazelle Chair offers women and their clinicians an alternative: a clinically researched, in-office treatment that demands no recovery time and does not interfere with everyday routines.
“Too many women are told that bladder leakage is simply something they have to accept after childbirth or menopause. It isn’t. ExMI has more than two decades of clinical evidence behind it, and through the Gazelle Chair we can now offer women a non-invasive, in-office option that involves no surgery, no medication, and no downtime. For providers, it’s a chance to finally address something their patients have been struggling with quietly for years.”
— Clinical Advisor, Bedrock Bioscience
In a Gazelle Chair session, the patient remains fully clothed while a bio-electric magnetic field reaches up to four inches into the body, activating the nerves and muscles of the pelvic floor. The pulses prompt the muscles to contract and relax at a regulated rhythm, re-educating the communication pathway between the brain and the pelvic floor throughout the treatment series. Since ExMI requires no direct skin contact and no anesthesia, individuals can go back to their normal activities straight after a 20-minute appointment.
The clinical foundation supporting the ExMI technology inside the Gazelle Chair covers more than 25 years. A 2020 randomized controlled trial published in BioMed Research International evaluated ExMI against standard pelvic floor muscle training and identified meaningful gains in continence and quality-of-life outcomes for those who received ExMI (Weber-Rajek et al., 2020). That study is one of 46 published investigations on ExMI listed at gazellechair.com/clinical-studies, covering urology, urogynecology, and pelvic rehabilitation literature. ExMI carries two 510(k) clearances from the U.S. Food and Drug Administration, is categorized as a Class II powered muscle stimulator, and each Gazelle Chair is built in the United States according to ISO-13485 quality standards. As with any clinical therapy, individual results may vary.
As with any magnetic stimulation modality, ExMI is not suitable for all patients. Pregnancy, a copper intrauterine device, ferromagnetic implants, a cardiac pacemaker, and severe cardiac arrhythmia are contraindications for ExMI treatment. Patients should review their complete medical background with a provider prior to beginning treatment.
“I was one of the first ten providers to bring the Gazelle Chair into my practice, and the response has been remarkable. Women have been searching for a real solution for years, and what keeps me excited is the results they get. It takes very little chair time, and the improvement in their quality of life speaks for itself.”
— Dr. J.L., one of the first Gazelle Chair providers
Bedrock Bioscience is the exclusive licensee for delivering ExMI technology, under the Gazelle Chair brand, to physicians (MDs), chiropractors (DCs), nurse practitioners (NPs), medspas, and wellness and longevity facilities seeking to provide their patients with a clinically studied, non-invasive alternative for incontinence. Women can go to gazellechair.com to find out more about the therapy, examine the supporting research, and locate a participating provider near them.
For additional details about the Gazelle Chair, including clinical studies and provider information, visit gazellechair.com.
Ricardo Ruiz
Bedrock Bioscience
+1 760-300-8163
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
